SCHEMBL26757983

SCHEMBL26757983

COCCCNC(=O)c1cc([N+](=O)[O-])ccc1N

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ KMT2A Q03164 3/20 0.55
▸ NPC1 O15118 2/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ MAPT P10636 4/20 0.51
▸ RAB9A P51151 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ LMNA P02545 1/20 0.48
▸ HPGD P15428 3/20 0.47
▸ POLB P06746 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ HTT P42858 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25425226 0.92 MEN1 (0.57) ALDH1A1KMT2ANPC1MEN1MAPT
SCHEMBL6939743 0.89 HPGD (0.52) SMN1; SMN2KMT2ANPC1MEN1MAPT
SCHEMBL26757997 0.86 MGLL (0.54) ALDH1A1SMN1; SMN2NPC1MAPTRAB9A
SCHEMBL6942718 0.84 MGLL (0.56) ALDH1A1SMN1; SMN2KMT2ANPC1MEN1
SCHEMBL26758023 0.84 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2KMT2ANPC1MEN1
SCHEMBL13753858 0.83 POLB (0.59) ALDH1A1KMT2ANPC1MEN1MAPT
SCHEMBL26757982 0.83 KMT2A (0.51) ALDH1A1SMN1; SMN2KMT2ANPC1MEN1
SCHEMBL6941386 0.83 MAPT (0.52) ALDH1A1SMN1; SMN2KMT2ANPC1MEN1
SCHEMBL26757991 0.82 KMT2A (0.50) ALDH1A1SMN1; SMN2KMT2ANPC1MEN1
SCHEMBL27557742 0.82 MAPT (0.60) ALDH1A1SMN1; SMN2KMT2ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2026-01-20 — — US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 — — US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 — — US disclosed
EP-4171569-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF Council of Scientific & Industrial Research (IN) 2023-05-03 — — EP disclosed
WO-2022003712-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2022-01-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC ALDH1A1 295/4885SMN1; SMN2 3760/4885KMT2A 3393/4885
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof ATG7, GOT1, ULK1 ALDH1A1 601/4885SMN1; SMN2 3400/4885KMT2A 2468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback